A MULTICENTER DOUBLE-BLIND-STUDY OF 3 DIFFERENT DOSES OF THE NEW CAMP-PHOSPHODIESTERASE INHIBITOR ROLIPRAM IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

被引:112
作者
FLEISCHHACKER, WW
HINTERHUBER, H
BAUER, H
PFLUG, B
BERNER, P
SIMHANDL, C
WOLF, R
GERLACH, W
JAKLITSCH, H
SASTREHERNANDEZ, M
SCHMEDINGWIEGEL, H
SPERNERUNTERWEGER, B
VOET, B
SCHUBERT, H
机构
[1] UNIV FRANKFURT,DEPT PSYCHIAT,W-6000 FRANKFURT,GERMANY
[2] UNIV VIENNA,DEPT PSYCHIAT,A-1010 VIENNA,AUSTRIA
[3] CANTONAL PSYCHIAT HOSP,SOLOTHURN,SWITZERLAND
[4] PSYCHIAT HOSP,GRAZ,AUSTRIA
[5] STATE PSYCHIAT HOSP,HALL,AUSTRIA
[6] SCHERING AG,RES LABS,BERLIN,GERMANY
关键词
ROLIPRAM; MAJOR DEPRESSIVE DISORDER; PHOSPHODIESTERASE INHIBITOR; ANTIDEPRESSANT;
D O I
10.1159/000118897
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A multicenter randomized 4-week interindividual double-blind study was carried out in 58 hospitalized patients with major depressive disorder (DSM III 296.23, 296.22, 296.33, 296.32, 296.53 and 296.52) to test the dose-effect relationship of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram: 3 X 0.25 mg, 3 X 0.50 mg and 3 X 1.00 mg rolipram/day. With respect to the desired effect, the 3 X 0.50 mg dosage stood out from the others in almost all relevant parameters. With respect to the response rate, the efficacy of the 3 X 0.25 mg dosage was about the same as that reported in the literature for placebo. The inferior performance of the 3 X 1.00 mg dosage compared to the 3 X 0.50 mg dosage might indicate a reverse U-shaped dose-effect relationship. There was good tolerance to all three dosages. There were no findings that might cast doubt on the safety of the dosages tested.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 21 条
[1]   A DOUBLE-BLIND COMPARATIVE TRIAL OF ZIMELIDINE, AMITRIPTYLINE, AND PLACEBO IN PATIENTS WITH MIXED ANXIETY AND DEPRESSION [J].
AMSTERDAM, JD ;
CASE, WG ;
CSANALOSI, E ;
SINGER, M ;
RICKELS, K .
PHARMACOPSYCHIATRY, 1986, 19 (03) :115-119
[2]  
AMSTERDAM JD, 1986, CURR THER RES CLIN E, V39, P87
[3]  
BALDESSARINI RJ, 1991, PHARMAKOTHERAPIE PSY, P107
[4]   A MULTICENTER DOUBLE-BLIND-STUDY OF 3 DIFFERENT DOSES OF THE NEW CAMP-PHOSPHODIESTERASE INHIBITOR ROLIPRAM IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER [J].
FLEISCHHACKER, WW ;
HINTERHUBER, H ;
BAUER, H ;
PFLUG, B ;
BERNER, P ;
SIMHANDL, C ;
WOLF, R ;
GERLACH, W ;
JAKLITSCH, H ;
SASTREHERNANDEZ, M ;
SCHMEDINGWIEGEL, H ;
SPERNERUNTERWEGER, B ;
VOET, B ;
SCHUBERT, H .
NEUROPSYCHOBIOLOGY, 1992, 26 (1-2) :59-64
[5]   ROLIPRAM VERSUS IMIPRAMINE IN INPATIENTS WITH MAJOR, MINOR OR ATYPICAL DEPRESSIVE DISORDER - A DOUBLE-BLIND DOUBLE-DUMMY STUDY AIMED AT TESTING A NOVEL THERAPEUTIC APPROACH [J].
BERTOLINO, A ;
CRIPPA, D ;
DIDIO, S ;
FICHTE, K ;
MUSMECI, G ;
PORRO, V ;
RAPISARDA, V ;
SASTREYHERNANDEZ, M ;
SCHRATZER, M .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1988, 3 (03) :245-253
[6]   IS PHOSPHODIESTERASE INHIBITION A NEW MECHANISM OF ANTIDEPRESSANT ACTION - A DOUBLE-BLIND DOUBLE-DUMMY STUDY BETWEEN ROLIPRAM AND DESIPRAMINE IN HOSPITALIZED MAJOR AND OR ENDOGENOUS DEPRESSIVES [J].
BOBON, D ;
BREULET, M ;
GERARDVANDENHOVE, MA ;
GUIOTGOFFIOUL, F ;
PLOMTEUX, G ;
SASTREYHERNANDEZ, M ;
SCHRATZER, M ;
TROISFONTAINES, B ;
VONFRENCKELL, R ;
WACHTEL, H .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1988, 238 (01) :2-6
[7]  
ECKMANN F, 1988, CURR THER RES CLIN E, V43, P291
[8]   FLUOXETINE RESPONSE - END-POINT VS PATTERN-ANALYSIS [J].
FIEVE, RR ;
GOODNICK, PJ ;
PESELOW, E ;
SCHLEGEL, A .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1986, 1 (04) :320-323
[9]  
GEYER KH, 1962, SUBSTANZEN THER GEGE, V101, P288
[10]   ROLIPRAM IN MAJOR DEPRESSIVE DISORDER - RESULTS OF A DOUBLE-BLIND COMPARATIVE-STUDY WITH IMIPRAMINE [J].
HEBENSTREIT, GF ;
FELLERER, K ;
FICHTE, K ;
FISCHER, G ;
GEYER, N ;
MEYA, U ;
SASTREYHERNANDEZ, M ;
SCHONY, W ;
SCHRATZER, M ;
SOUKOP, W ;
TRAMPITSCH, E ;
VAROSANEC, S ;
ZAWADA, E ;
ZOCHLING, R .
PHARMACOPSYCHIATRY, 1989, 22 (04) :156-160